When Drug Companies Are Too Big to Punish

Fines have become just another cost of doing business for companies that cause mass harm. It's time to demand consequences that actually matter.

The current system of fining pharmaceutical giants for massive public health disasters, like the Vioxx scandal and the opioid crisis, is a failed model of accountability that protects the very executives who make the decisions.

• Big Pharma treats huge fines as a simple cost of doing business.

• The Vioxx case proved a company could cause mass harm, pay up, and thrive.

• Unlike in other fields, individual pharma executives are rarely held responsible.

• Real justice means punishing the decision-makers, not just the company's bank account.

The Price of a Life, Itemized on a Balance Sheet

I keep a small box in my bathroom closet for basic medicines—pain relievers, allergy pills, cold remedies. I’d guess you do, too. We place a certain faith in the companies that make these products. We trust that the medicine is safe, that the people behind it have acted in good faith, and that its benefits outweigh its risks.

This trust is the bedrock of modern medicine. But what happens when it's shattered? And more importantly, what happens when the consequences for shattering it are little more than a financial slap on the wrist?

I’ve come to believe that the pharmaceutical industry has a unique and dangerous form of the "too big to fail" problem. When a giant bank teeters, the government may step in to prevent economic collapse. But when a giant drug company is found to have caused a public health catastrophe, the company simply pays a fine. The enterprise survives because we need its other life-saving drugs.

The fine, no matter how many billions it contains, becomes just another line item in the budget. This is not justice. It’s a business expense.

The Vioxx Precedent: Paying the Toll and Driving On

Let's look back to the early 2000s and the case of Vioxx, Merck's blockbuster painkiller. The drug was a massive success until research confirmed it greatly increased the risk of heart attacks and strokes. Internal documents later suggested the company knew about the risks long before it pulled the drug from the market. The fallout was immense. Estimates suggest the drug was linked to tens of thousands of American deaths.

What was the final reckoning? Merck paid nearly a billion dollars in penalties and billions more to settle civil lawsuits. That sounds like a staggering sum. But for a company of Merck's size, it was survivable. Today, Merck is one of the largest and most respected pharmaceutical companies in the world. The corporation took the hit, absorbed the cost, and moved on. The penalty, while huge, did little to challenge the corporate structure or the individuals who oversaw the Vioxx strategy.

It set a precedent: causing mass harm was a punishable, but ultimately manageable, corporate error.

The Sackler Playbook: Personal Wealth in Exchange for Public Ruin

If Vioxx set the precedent, the Sackler family and Purdue Pharma perfected the strategy. They took a powerful, addictive opioid, OxyContin, and marketed it with a ferocity and deceit that ignited a national crisis. They told doctors it was safe and addiction was rare, all while knowing how dangerous the drug truly was. The result has been a multi-decade catastrophe that has cost hundreds of thousands of lives and torn families apart.

When the reckoning finally came, the Sacklers used the corporation as a shield. They funneled billions of dollars out of Purdue Pharma into their personal accounts. Then, as lawsuits mounted, they pushed the company into bankruptcy. Their proposed settlement involved giving up the company and paying a few billion dollars—a fraction of their estimated fortune—in exchange for broad immunity from any future civil claims.

Think about that. They oversaw a public health disaster, extracted immense personal wealth from it, and then used legal maneuvers to protect that wealth. The company could fail, but the architects of its ruin would walk away as billionaires.

This is not just a failure of justice; it is a moral catastrophe that creates a playbook for others to follow.

What Accountability Ought to Look Like

We don't accept this model in other high-stakes fields. When a plane crashes due to a known, ignored defect, we expect engineers and executives to be held personally accountable. When a financial firm commits massive fraud, laws like Sarbanes-Oxley open the door for executives to face prison time.

Real accountability in the pharmaceutical world would look similar. It would mean clawing back every dollar of executive compensation that was tied to a fraudulently marketed drug. It would mean making it easier to hold board members and C-suite leaders criminally liable when they are shown to have knowingly hidden data or approved a marketing plan that put lives at risk. A fine hurts a company's stock price for a quarter or two.

The prospect of losing your personal fortune or your freedom permanently changes behavior. The pattern of prioritizing profits over patient safety is destined to repeat.

Final Thought

The medicines in my cabinet are supposed to be instruments of healing. But they cannot come from a system that allows the people who create and market them to cause immense harm without consequence. We have a moral obligation to demand a new standard of accountability, one that recognizes that the price of betrayal on this scale can never be paid with money alone.